enteroviru
infect
gener
manifest
mild
hand
foot
mouth
diseas
report
caus
sever
neurolog
complic
high
mortal
rate
treatment
option
remain
limit
due
lack
antivir
octaguanidiniumconjug
morpholino
oligom
vivomo
singlestrand
dnalik
antisens
agent
readili
penetr
cell
reduc
gene
express
steric
block
complementari
rna
sequenc
studi
inhibitori
effect
three
vivomo
complementari
intern
ribosom
entri
site
ire
rnadepend
rna
polymeras
rdrp
test
rd
cell
target
ire
show
signific
viral
plaqu
reduct
log
pfuml
respect
vivomo
reduc
viral
rna
copi
viral
capsid
express
rd
cell
dosedepend
manner
contrast
target
rdrp
exhibit
less
antivir
activ
remain
activ
administ
either
h
within
h
infect
exhibit
antivir
activ
polioviru
pv
coxsackieviru
show
antivir
activ
pv
irestarget
inhibit
rna
translat
resist
mutant
aros
serial
passag
presenc
none
isol
singl
c
substitut
nucleotid
posit
suffici
confer
resist
find
suggest
irestarget
vivomo
good
antivir
candid
treat
earli
infect
favor
candid
broader
antivir
spectrum
enterovirus
refractori
antivir
resist
enteroviru
singlestrand
positivesens
rna
viru
usual
caus
mild
hand
foot
mouth
diseas
hfmd
character
fever
papulovesicular
rash
palm
sole
recent
year
infect
also
associ
neurolog
complic
high
mortal
among
infant
young
children
year
old
date
effect
antivir
agent
avail
clinic
use
shang
et
al
tan
et
al
thu
urgent
need
develop
effect
antivir
agent
treat
infect
consid
morbid
caus
new
approach
develop
therapeut
need
number
promis
rnabas
therapeut
design
inhibit
infect
shown
promis
result
includ
sirna
shrna
deng
et
al
sim
et
al
tan
et
al
b
wu
et
al
howev
limit
rnabas
therapeut
short
halflif
requir
deliveri
agent
might
toxic
host
therefor
nucleic
acidbas
therapeut
design
possess
favor
pharmacolog
properti
vivo
stabil
low
toxic
phosphorodiamid
morpholino
oligom
pmo
singlestrand
dnalik
compound
abil
bind
mrna
inhibit
gene
express
steric
blockag
complementari
rna
pmo
highli
nucleaseresist
requir
rnase
h
catalyt
protein
activ
kole
et
al
summerton
pmo
conjug
variou
cellpenetr
compound
cellpenetr
peptid
octaguanidinium
dendrim
abl
enhanc
uptak
cell
moulton
jiang
peptid
conjugatedpmo
ppmo
demonstr
inhibit
variou
viral
infect
includ
ebola
viru
warfield
et
al
west
nile
viru
dea
et
al
dengu
viru
kinney
et
al
sindbi
viru
paessler
et
al
coronaviru
neuman
http
opriessnig
et
al
patel
et
al
footandmouth
diseas
viru
vagnozzi
et
al
polioviru
rhinoviru
stone
et
al
coxsackieviru
yuan
et
al
studi
three
octaguanidinium
dendrim
conjugatedmorpholino
oligom
vivomo
target
intern
ribosom
entri
site
ire
core
sequenc
rnadepend
rna
polymeras
rdrp
test
inhibitori
effect
demonstr
two
vivomo
target
ire
core
sequenc
show
signific
inhibit
infect
rhabdomyosarcoma
rd
atcc
cell
grown
dulbecco
modifi
eagl
medium
dmem
hyclon
supplement
fetal
bovin
serum
fb
strain
genbank
access
number
brcr
genbank
access
number
genbank
access
number
coxsackieviru
pv
chikungunya
viru
chikv
strain
genbank
access
number
propag
rd
cell
vivomo
synthes
gene
tool
llc
usa
vivomo
design
complementari
strain
ire
stemloop
vvi
rdrp
gene
tabl
fig
vivomo
dissolv
phosphat
buffer
salin
pb
concentr
mm
cytotox
vivomo
evalu
use
cell
titer
aqueou
cell
prolifer
reagent
promega
accord
manufactur
instruct
rd
cell
seed
cell
cell
within
well
plate
plate
respect
incub
overnight
co
overnight
incub
growth
medium
remov
replac
inoculum
multipl
infect
moi
pfu
per
cell
incub
h
incub
inoculum
remov
replenish
mainten
medium
dmem
fb
without
vivomo
inhibitori
effect
vivomo
evalu
plaqu
assay
taqman
realtim
rtpcr
western
blot
analysi
h
postinfect
hpi
previous
describ
tan
et
al
western
blot
signal
enhanc
use
supersign
western
blot
enhanc
pierc
biotechnolog
vivomo
ad
rd
cell
variou
time
point
rel
viral
inocul
rd
cell
preincub
vivomo
final
concentr
lm
h
inocul
moi
concurr
studi
vivomo
ad
rd
cell
h
follow
replac
medium
without
vivomo
postinfect
studi
rd
cell
infect
h
vivomo
appli
viral
titer
experi
quantit
hpi
plaqu
assay
evalu
efficaci
vivomo
differ
enterovirus
includ
pv
rd
cell
preincub
vivomo
final
concentr
lm
h
viral
tabl
sequenc
vivomo
target
locat
rna
sequenc
inocul
moi
h
viral
titer
determin
hpi
plaqu
assay
chikv
use
neg
control
viru
experi
strain
infecti
clone
construct
use
fulllength
genom
pcr
approach
accord
yeh
et
al
modif
primer
involv
infecti
clone
construct
list
tabl
fulllength
genom
rtpcr
perform
superscript
iii
revers
transcriptas
invitrogen
iproof
highfidel
polymeras
biorad
use
eagir
primer
express
enhanc
green
fluoresc
protein
egfp
construct
overlap
extens
pcr
strategi
use
highfidel
polymeras
neb
egfp
gene
fuse
genom
utr
gene
follow
cleavag
site
aittl
previous
describ
shang
et
al
fulllength
pcr
product
clone
pcrxltopo
invitrogen
vitro
transcript
perform
linear
dna
use
larg
scale
rna
product
system
promega
rna
transfect
rd
cell
use
lipofectamin
invitrogen
accord
manufactur
instruct
cell
free
translat
assay
perform
lg
vitro
transcrib
rna
use
human
coupl
ivt
kit
pierc
biotechnolog
either
presenc
absenc
vivomo
accord
manufactur
instruct
aliquot
vitro
translat
sampl
subject
sdspage
western
blot
analysi
describ
previous
immunoblot
develop
western
ecl
substrat
biorad
detect
chemiluminesc
rd
cell
plate
infect
hour
incub
inoculum
remov
replac
mainten
medium
contain
lm
vivomo
egfp
express
observ
hpi
use
fluoresc
microscopi
passag
rd
cell
increas
concentr
either
first
passag
rd
cell
infect
moi
h
inoculum
remov
replac
mainten
medium
contain
lm
select
passag
ad
supernat
new
rd
cell
virus
passag
concentr
rang
lm
lm
follow
passag
four
time
lm
identifi
mutat
confer
resist
vivomo
viral
rna
individu
plaqu
popul
amplifi
subject
dna
sequenc
point
mutat
incorpor
infecti
clone
use
quickchang
lightn
sitedirect
mutagenesi
kit
agil
technolog
accord
manufactur
instruct
four
mutant
construct
differ
nucleotid
substitut
target
region
tabl
degre
resist
evalu
use
inhibitori
assay
describ
section
data
present
mean
standard
deviat
sd
obtain
least
two
independ
biolog
replic
error
bar
repres
sd
statist
signific
calcul
use
mannwhitney
test
p
valu
consid
statist
signific
evalu
effect
vivomo
infect
rd
cell
rd
cell
treat
vivomo
hour
infect
shown
fig
vivomo
target
ire
stemloop
region
exhibit
signific
antivir
activ
infect
reduct
virusinduc
cpe
fig
plaqu
format
fig
rna
fig
capsid
express
fig
dosedepend
manner
significantli
reduc
plaqu
format
log
lm
respect
signific
inhibit
observ
concentr
higher
lm
ic
valu
lm
lm
respect
howev
exhibit
less
inhibitori
effect
infect
rd
cell
plaqu
reduct
log
pfuml
fig
vivomoc
homolog
sequenc
genom
inhibitori
effect
strain
test
none
vivomo
caus
reduct
cell
viabil
concentr
less
lm
measur
mt
assay
fig
character
efficaci
vivomo
multipl
time
point
rel
infect
vivomo
appli
h
h
infect
remain
effect
administ
infect
howev
efficaci
reduc
treatment
delay
vivomo
ad
togeth
rd
cell
h
inhibitori
effect
reduc
could
result
incomplet
uptak
vivomo
cell
nonetheless
antivir
effect
retain
irestarget
vivomo
even
administ
hpi
plaqu
inhibit
observ
inhibitori
effect
infect
administ
h
infect
hpi
fig
next
investig
whether
vivomo
could
inhibit
differ
strain
well
picornavirus
evalu
vivomo
two
strain
brcr
tabl
sequenc
vitro
transcrib
infecti
rna
target
sequenc
sequenc
mismatch
es
pv
chikv
control
viru
target
highli
conserv
region
ire
stemloop
structur
exhibit
signific
inhibitori
activ
strain
brcr
pv
viral
plaqu
reduct
rang
log
pfuml
fig
howev
exhibit
antivir
activ
strain
brcr
pv
fig
strain
brcr
singl
nucleotid
mismatch
middl
target
site
fig
remain
sensit
treatment
efficaci
log
pfuml
reduct
significantli
lower
compar
log
pfuml
reduct
could
due
three
nucleotid
mismatch
pv
five
nucleotid
mismatch
complet
resist
inhibitori
effect
vivomo
show
inhibit
chikv
infect
investig
mechan
action
antivir
vivomo
cellfre
translat
analysi
use
depict
fig
presenc
either
significantli
block
iresdepend
translat
compar
control
exhibit
reduc
efficaci
compar
irestarget
vivomo
inhibit
assay
presenc
greatli
reduc
egfp
express
rd
cell
hpi
fig
explor
whether
could
becom
resist
vivomo
treatment
serial
passag
presenc
increas
concentr
either
interestingli
mutant
resist
isol
eight
passag
fail
isol
mutant
resist
investig
determin
resist
viral
rna
isol
resist
popul
sequenc
singl
point
mutat
c
posit
suffici
confer
resist
fig
character
loss
inhibitori
activ
construct
mutant
carri
differ
mismatch
target
site
tabl
inhibitori
effect
mutant
object
observ
hpi
total
infecti
particl
total
viral
protein
harvest
hpi
evalu
b
plaqu
assay
c
quantit
taqman
realtim
pcr
western
blot
analysi
respect
viral
capsid
protein
detect
mous
monoclon
antibodi
millipor
cellular
bactin
detect
use
mous
antibactin
monoclon
antibodi
sigma
data
present
obtain
least
two
independ
biolog
replic
fig
cell
viabil
analysi
variou
concentr
vivomo
incub
rd
cell
cell
h
mainten
medium
dmem
supplement
fb
follow
mt
assay
use
cell
titer
aqueou
one
solut
cell
prolifer
promega
absorb
read
nm
obtain
use
microtit
plate
reader
h
incub
percentag
cell
viabil
determin
multipli
ratio
absorb
read
obtain
cell
treat
vivomo
nontreat
cell
data
present
obtain
least
two
independ
biolog
replic
evalu
mismatch
rna
target
sequenc
design
reflect
like
natur
variat
would
aris
sequenc
shown
fig
carri
singl
point
mutat
posit
c
substitut
requir
higher
concentr
achiev
similar
inhibitori
effect
compar
wild
type
singl
point
mutat
middl
target
sequenc
c
substitut
posit
remain
sensit
reduc
inhibitori
efficaci
compar
wild
type
increas
number
mutat
target
sequenc
significantli
reduc
inhibitori
efficaci
viral
plaqu
inhibit
lm
reduc
carri
point
mutat
end
target
sequenc
viral
plaqu
inhibit
reduc
number
nucleotid
mismatch
increas
three
date
fda
approv
vaccin
avail
prevent
infect
treatment
option
remain
limit
due
lack
effect
antivir
chong
et
al
shang
et
al
highli
negativelycharg
compound
like
suramin
analog
disrupt
virushost
receptor
interact
ineffect
mutant
acquir
substitut
capsid
protein
arita
et
al
singl
point
mutat
egfp
express
nuclei
shown
green
blue
respect
data
present
obtain
least
two
independ
biolog
replic
interpret
refer
color
figur
legend
reader
refer
web
version
articl
suffici
confer
resist
capsid
binder
shih
et
al
therefor
urgent
need
develop
effect
antivir
agent
treat
patient
sever
infect
use
antisens
mechan
inhibit
pathogen
replic
investig
shown
promis
result
fomivirsen
phosphorothio
oligonucleotid
antisens
agent
use
intravitr
treatment
cytomegaloviru
retin
antisens
agent
approv
fda
date
de
smet
et
al
advantag
vivomo
rnabas
antisens
oligom
nucleaseresist
readili
penetr
cell
kole
et
al
moulton
jiang
advantag
peptidebas
cell
penetr
molecul
suscept
proteas
degrad
impact
effect
ppmo
youngblood
et
al
amongst
three
vivomo
examin
two
vivomo
target
ire
stemloop
region
exhibit
signific
antivir
activ
vivomo
block
viral
rna
translat
cellfre
inhibit
assay
well
cellbas
egfp
report
inhibit
assay
previou
studi
also
report
pmo
target
posit
strand
ire
region
aug
start
codon
site
effect
compar
pmo
target
region
viral
rna
stone
et
al
vagnozzi
et
al
yuan
et
al
pmo
may
bind
complementari
viral
rna
disrupt
integr
ire
stemloop
secondari
tertiari
structur
henc
arrest
iresdepend
translat
kole
et
al
warren
et
al
pmo
like
block
ribosom
subunit
bind
viral
rna
vicin
stemloop
v
picornavir
type
ire
belsham
furthermor
suggest
ire
stemloop
vvi
interact
iresspecif
transact
factor
fusebind
protein
heterogen
nuclear
ribonucleoprotein
al
lin
et
al
b
shih
et
al
unlik
synthet
doublestrand
sirna
involv
cleavag
mrna
pmo
translationsuppress
oligonucleotid
lead
rna
degrad
kole
et
al
warren
et
al
could
explain
sirna
target
similar
viral
sequenc
effect
act
translat
suppress
oligonucleotid
downregul
gene
express
via
steric
blockag
irestarget
exhibit
broadspectrum
activ
multipl
enterovirus
differ
antivir
efficaci
could
result
ire
stemloop
structur
differ
enterovirus
affect
access
vivomo
target
site
dia
stein
studi
mutant
resist
carri
singl
substitut
c
posit
fail
isol
resist
even
eight
passag
vitro
impli
target
region
intoler
mutat
natur
mutagenesi
studi
confirm
posit
mutat
number
mutat
affect
antivir
efficaci
rd
cell
singl
mismatch
present
middl
target
sequenc
c
substitut
posit
toler
mutat
appear
end
target
site
c
substitut
posit
find
correl
well
previou
find
pv
fmdv
wnv
show
resist
ppmo
also
carri
singl
point
mutat
end
ppmotarget
sequenc
stone
et
al
vagnozzi
et
al
zhang
et
al
similar
observ
made
influenza
viru
degre
inhibit
associ
number
mismatch
ge
et
al
summari
establish
two
critic
locat
involv
viral
translat
initi
genom
target
vivomo
antivir
intervent
vivomo
work
well
low
micromolar
concentr
inhibit
infect
show
littl
cytotox
rd
cell
potent
inhibit
sever
enterovirus
rais
possibl
could
develop
broadspectrum
antivir
agent
furthermor
degre
toler
mismatch
vivomo
suggest
favor
characterist
use
potenti
antivir
agent
supplementari
data
associ
articl
found
onlin
version
http
effect
sequenc
mismatch
target
rna
inhibit
assay
sever
vitro
transcrib
rna
differ
number
nucleotid
mismatch
target
region
describ
section
analyz
viral
titer
quantit
hpi
use
standard
plaqu
assay
data
present
obtain
least
two
independ
biolog
replic
